AR029130A1 - Gen enzimatico y sus productos de expresion - Google Patents

Gen enzimatico y sus productos de expresion

Info

Publication number
AR029130A1
AR029130A1 ARP010102776A ARP010102776A AR029130A1 AR 029130 A1 AR029130 A1 AR 029130A1 AR P010102776 A ARP010102776 A AR P010102776A AR P010102776 A ARP010102776 A AR P010102776A AR 029130 A1 AR029130 A1 AR 029130A1
Authority
AR
Argentina
Prior art keywords
gene
protein
acid sequence
amino acid
sequence represented
Prior art date
Application number
ARP010102776A
Other languages
English (en)
Spanish (es)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR029130A1 publication Critical patent/AR029130A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1096—Transferases (2.) transferring nitrogenous groups (2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ARP010102776A 2000-06-13 2001-06-12 Gen enzimatico y sus productos de expresion AR029130A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000176631 2000-06-13
JP2000290679A JP4601143B2 (ja) 2000-06-13 2000-09-25 新規酵素遺伝子およびその発現産物

Publications (1)

Publication Number Publication Date
AR029130A1 true AR029130A1 (es) 2003-06-04

Family

ID=26593812

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010102776A AR029130A1 (es) 2000-06-13 2001-06-12 Gen enzimatico y sus productos de expresion

Country Status (15)

Country Link
US (1) US7091018B2 (https=)
EP (1) EP1291429B1 (https=)
JP (1) JP4601143B2 (https=)
KR (1) KR100882407B1 (https=)
CN (1) CN100390286C (https=)
AR (1) AR029130A1 (https=)
AT (1) ATE407212T1 (https=)
AU (2) AU6424501A (https=)
CA (1) CA2412880C (https=)
DE (1) DE60135650D1 (https=)
DK (1) DK1291429T3 (https=)
ES (1) ES2312442T3 (https=)
PT (1) PT1291429E (https=)
TW (1) TWI232883B (https=)
WO (1) WO2001096574A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE506614T1 (de) * 2005-06-20 2011-05-15 Exelixis Inc Gfats als modifikatoren des axin-wegs und verwendungsverfahren
EP1951030B1 (en) * 2005-10-05 2015-02-25 Bayer Intellectual Property GmbH Improved methods and means for producings hyaluronan
JP5325576B2 (ja) * 2006-06-30 2013-10-23 北海道システム・サイエンス株式会社 核酸導入用組成物
CN103301447B (zh) * 2013-06-25 2014-12-31 哈尔滨医科大学 DNA-PKcs在制备改变肿瘤细胞对MTX耐药性的药物中的应用
CN112980914A (zh) * 2019-12-12 2021-06-18 中国科学院大连化学物理研究所 Gfpt1基因作为靶点在筛选抗肿瘤药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993021330A1 (en) * 1992-04-22 1993-10-28 Zymogenetics, Inc. Human glutamine:fructose-6-phosphate amino-transferase
JPH1018683A (ja) * 1996-06-29 1998-01-20 Tesco Joho Center:Kk 吊下扉のレール装置
US5876713A (en) * 1996-08-13 1999-03-02 Takeda Chemical Industries Ltd Glutamine: fructose-6-phosphate amidotransferase, its production and use
JP4175680B2 (ja) * 1996-08-13 2008-11-05 武田薬品工業株式会社 新規タンパク質およびそのｄｎａ
AU2216300A (en) * 1998-12-22 2000-07-12 G.D. Searle & Co. Glutamine: fructose-6-phosphate aminotransferase ii enzyme and their encoding nucleic acids

Also Published As

Publication number Publication date
CN1436239A (zh) 2003-08-13
AU6424501A (en) 2001-12-24
PT1291429E (pt) 2008-12-15
JP2002065284A (ja) 2002-03-05
WO2001096574A1 (en) 2001-12-20
ES2312442T3 (es) 2009-03-01
CA2412880A1 (en) 2002-12-13
EP1291429B1 (en) 2008-09-03
US20040132020A1 (en) 2004-07-08
TWI232883B (en) 2005-05-21
US7091018B2 (en) 2006-08-15
EP1291429A1 (en) 2003-03-12
DE60135650D1 (de) 2008-10-16
DK1291429T3 (da) 2009-01-19
AU2001264245B2 (en) 2006-04-27
KR100882407B1 (ko) 2009-02-05
EP1291429A4 (en) 2004-05-26
JP4601143B2 (ja) 2010-12-22
KR20030011868A (ko) 2003-02-11
CA2412880C (en) 2010-05-04
ATE407212T1 (de) 2008-09-15
CN100390286C (zh) 2008-05-28

Similar Documents

Publication Publication Date Title
NZ621196A (en) Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
EP2337790B1 (en) Clostridial neurotoxins with altered persistency
UA97953C2 (uk) Стабілізовані поліпептиди інсуліноподібного фактора росту
MX339277B (es) Agente inductor de inmunidad.
EA039105B1 (ru) Катионные нейротоксины
TR200000649T2 (tr) PTHrP analogları kullanılarak kırıkların iyileştirilmesi.
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
HRP20110242T1 (hr) Formulacija s fuzijskim proteinom glp-1-fc
ATE456959T1 (de) Stabilisierte tumorantigen-mrna mit erhöhtem g/c- gehalt
CN110023329A (zh) 作为肽类三重glp1/胰高血糖素/gip受体激动剂的新化合物
EP2476697A3 (en) Peptide vaccines for cancers expressing MPHOSPH1 or DEPDC1 polypeptides
PE20090932A1 (es) Compuestos que exhiben actividad antagonista del glucagon y agonista del glp-1
RU2012123642A (ru) Аналоги инсулина, содержащие хлорированные аминокислоты
RU2009134725A (ru) Варианты трансглутаминазы с улучшенной специфичностью
NZ599161A (en) Method for activation of helper t cell and composition for use in the method
Asami et al. Serum stability of selected decapeptide agonists of KISS1R using pseudopeptides
CO6260151A2 (es) Peptido de cdh3 y agente medicinal que comprende al mismo
MX2008009493A (es) Peptido novedoso y uso del mismo.
EA201990856A1 (ru) Новые противомикробные агенты против бактерий enterococcus
WO2004080957A3 (en) Use of adnf polypeptides for treating anxiety and depression
AR029130A1 (es) Gen enzimatico y sus productos de expresion
EA202090802A1 (ru) Пептидная композиция для лечения повреждений, связанных с возбуждающей нейротоксичностью
BR0318594A (pt) proteìna recombinante que possui um efeito anticancerìgeno, seu gene de codificação e usos desta
ATE490324T1 (de) Nukleinsäuren kodierend für polypeptide mit chips aktivität
NZ591827A (en) Biologically active peptides comprising PTTKTYFPHF and their uses in the manufacture of a medicament for modulating immune reaction in a radiotherapy-induced immuno-compromised subject

Legal Events

Date Code Title Description
FA Abandonment or withdrawal